Why the study?
Does co-treatment with doxorubicin and pyrrolidine dithiocarbamate overcome doxorubicin resistance and reduce tumor growth in Bcl-xL-overexpressing hepatoma cells?
Population
Chang-L liver cells, human hepatocytes, Bcl-xL-overexpressing Chang-L cells, several hepatocellular…
Comparison
Co-treatment with doxorubicin and pyrrolidine… vs Mono-treatment with doxorubicin or pyrrolidine…
Design
Preclinical
Authors
Loading...
PDTC may protect hepatocytes from DOX toxicity while sensitizing resistant cells; leaves open in vivo efficacy and clinical translation.
Does co-treatment with doxorubicin and pyrrolidine dithiocarbamate overcome doxorubicin resistance and reduce tumor growth in Bcl-xL-overexpressing hepatoma cells?
Co-treatment with doxorubicin and pyrrolidine dithiocarbamate overcomes doxorubicin resistance in Bcl-xL-overexpressing hepatoma cells by inducing paraptosis, offering a potential therapeutic strategy.
Park et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: